AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
Completed
NCIC Clinical Trials Group
Phase 1
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as
paclitaxel, carboplatin, or capecitabine, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together
with chemotherapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of AZD2171 when given
together with chemotherapy in treating patients with advanced non-small cell lung cancer
(closed to enrollment as of 8/9/07), colorectal cancer, or other cancer suitable to
capecitabine treatment.
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
Completed
National Cancer Institute (NCI)
Phase 2
This phase II trial studies how well cediranib maleate works in treating patients with
recurrent or metastatic kidney cancer that cannot be removed by surgery. Cediranib maleate
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Completed
National Cancer Institute (NCI)
Phase 2
AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial
is studying how well AZD2171 works in treating patients with locally advanced or metastatic
liver cancer.
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Completed
National Cancer Institute (NCI)
Phase 2
This phase II trial is studying how well AZD2171 works in treating patients with recurrent or
stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the
tumor and by blocking some of the enzymes needed for cell growth.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
